Corcept Therapeutics (CORT) Tops Q1 EPS by 3c, increases guidance
Tweet
Share
E-mailGet Alerts CORT Hot Sheet
Price: $88.40 -0.09%
Revenue Growth %: +12.1%
Financial Fact:
Net loss and comprehensive loss: 2.59M
Today's EPS Names:
PKE, LNN, More
Revenue Growth %: +12.1%
Financial Fact:
Net loss and comprehensive loss: 2.59M
Today's EPS Names:
PKE, LNN, More
Join SI Premium – FREE
Corcept Therapeutics (NASDAQ: CORT) reported Q1 EPS of $0.25, $0.03 better than the analyst estimate of $0.22. Revenue for the quarter came in at $146.81 million versus the consensus estimate of $141.19 million.
GUIDANCE:
Corcept Therapeutics sees FY2024 revenue of $620-650 million, versus the consensus of $610.6 million.
For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Lucid reports Q2 output, names new CFO and five other leaders
- Lindsay (LNN) Tops Q3 EPS by 18c, Misses on Revenue
- General Mills (GIS) PT Lowered to $42 at Freedom Broker
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
